Interview with Michael Pehl, Managing Director, Celgene Germany
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Address: Landsteinerstr. 5, D-63303 Dreieich,Germany
Tel: 49 – 6103 / 801 – 0
Web: http://www.biotest.de/ww/de/pub/home.cfm
Biotest is a company specialising in innovative haematology and immunology products with the holistic approach of a global pharmaceutical, diagnostics and biotherapeutics group. Its approximately 2,000 employees develop, manufacture and sell medicinal products for the treatment of blood and immune diseases as well as reagents and systems for diagnostic purposes in transfusion and transplantation medicine. Biotest is, in addition, one of the leading manufacturers of products for the hygiene monitoring of air and work surfaces.The most important starting material for our pharmaceutical products is human blood plasma which we process into effective and highly pure medicinal products in one of the world’s most modern production facilities in Europe. Our products are used in the treatment of life-threatening diseases such as coagulation disorders (haemophilia), severe infections or disorders of the immune system.
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
See our Cookie Privacy Policy Here
